Camber releases generic Daliresp
Roflumilast tablets are indicated as a treatment to reduce the risk of exacerbations in patients with severe COPD.
Camber is offering roflumilast 250 mcg tablets, the generic of Daliresp.
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Roflumilast 250 mcg tablets are available in 20 and 28 unit-dose cartons.
[Read more: Camber intros generic Namenda]
Roflumilast tablets also are available in 500 mcg strength in 30- and 90-ct. bottles.